Current Report Filing (8-k)
September 22 2021 - 8:06AM
Edgar (US Regulatory)
0001130598
false
0001130598
2021-09-22
2021-09-22
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
September 22, 2021
Onconova Therapeutics, Inc.
(Exact name of registrant as specified in its
charter)
Delaware
|
|
001-36020
|
|
22-3627252
|
(State or other jurisdiction
of incorporation )
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
12 Penns Trail
Newtown, PA
|
|
18940
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (267) 759-3680
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, par value $0.01 per share
|
|
ONTX
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ¨
On September 22, 2021, Onconova Therapeutics,
Inc. issued a press release announcing preliminary data from an investigator-initiated Phase 1/2a trial of oral rigosertib plus the immune
checkpoint inhibitor nivolumab in advanced KRAS mutated (KRAS+) non-small cell lung cancer. The data support the anti-cancer activity
of rigosertib-nivolumab combination therapy in this indication and show that the doublet has been well tolerated to-date. Three quarters
of patients enrolled in the trial have failed two or more lines of prior therapy and all have failed immune checkpoint inhibitors in various
combinations. The full text of the press release is filed as Exhibit 99.1 hereto and is incorporated herein by reference.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ONCONOVA THERAPEUTICS,
INC.
|
|
|
Date: September 22, 2021
|
/s/ MARK GUERIN
|
|
Name: Mark Guerin
|
|
Title: Chief Financial Officer
|
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Apr 2023 to Apr 2024